Holy Stone Healthcare’s IBD98-M Approved for Phase IIa Clinical Trial in Italy.
Holy Stone Healthcare participates at 5th World Congress on Cancer Therapy during September 28-30 at Atlanta, Georgia, USA
2015 Bio International convention, Philadelphia, PA
HSHC presented two scientific posters at the 2014 ISSX / JSSX Joint Meeting, San Francisco, CA
Holy Stone Healthcare Receives FDA Approval to Initiate Phase 1 study of IBD98-M
Holy Stone Healthcare exhibited in 2014 BIO Conference
Good news comes in pairs for Holy Stone Healthcare! Holy Stone Healthcare’s Hsinchu Plant has passed GMP pilot plant evaluation, and “The new drug development plan of the new compound IBD98-M on inflammatory bowel diseases” was also granted subsidies after passing the review screening.
Holy Stone Healthcare Co., Ltd. is set to list on Taiwan’s emerging stock market on December 13.